LEASE AGREEMENTLease Agreement • March 7th, 2024 • Cartesian Therapeutics, Inc. • Pharmaceutical preparations
THIS LEASE AGREEMENT is made as of this 11th day of May, 2018, between 704 Quince Orchard Owner, LLC, a Delaware limited liability company ("Landlord"), and Cartesian Therapeutics, Inc., a Delaware Corporation ("Tenant").
SECOND AMENDMENT TO LEASE AGREEMENTLease Agreement • March 7th, 2024 • Cartesian Therapeutics, Inc. • Pharmaceutical preparations
THIS SECOND AMENDMENT TO LEASE AGREEMENT (this “Second Amendment”) is dated as of May 3, 2021, by and between 704 QUINCE ORCHARD OWNER, LLC, a Delaware limited liability company, having an address at 26 North Euclid Avenue, Pasadena, California 91101 (“Landlord”), and CARTESIAN THERAPEUTICS, INC., a Delaware corporation, having an address at Suite 210, 704 Quince Orchard Road, Gaithersburg, Maryland 20878 (“Tenant”).
LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • March 7th, 2024 • Cartesian Therapeutics, Inc. • Pharmaceutical preparations • New York
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential.
FIRST AMENDMENT TO LEASE AGREEMENTLease Agreement • March 7th, 2024 • Cartesian Therapeutics, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO LEASE AGREEMENT (“this First Amendment”) is dated as of March 22, 2021 (“Effective Date”), by and between 704 QUINCE ORCHARD OWNER, LLC, a Delaware limited liability company, having an address at 26 North Euclid Avenue, Pasadena, California 91101 (“Landlord”), and CARTESIAN THERAPEUTICS, INC., a Delaware corporation, having an address at Suite 210, 704 Quince Orchard Road, Gaithersburg, Maryland 20878 (“Tenant”).
LEASE AGREEMENTLease Agreement • March 7th, 2024 • Cartesian Therapeutics, Inc. • Pharmaceutical preparations
THIS LEASE AGREEMENT (this “Lease”) is made and is effective this 28th day of February, 2024 (“Effective Date”) by and between 7495 RP, LLC a Maryland limited liability company having an address at 5377 Jackson Mountain Road, Frederick, Maryland 21702 (“Landlord”), and CARTESIAN THERAPEUTICS, INC., a Delaware corporation, having a headquarters address at 704 Quince Orchard Road (Suite 140), Gaithersburg, Maryland 20878 (“Tenant”). Following the Commencement Date (as defined below), Tenant’s address for notice purposes shall be at the Premises.
LICENSE AND DEVELOPMENT AGREEMENTLicense and Development Agreement • March 7th, 2024 • Cartesian Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 1 (this “Amendment No. 1”) to the License and Development Agreement, dated as of June 11, 2020 (the “Agreement”), is entered into as of October 31, 2023 (the “Amendment No. 1 Execution Date”), by and between SELECTA BIOSCIENCES, INC., a Delaware corporation having its principal place of business at 65 Grove Street, Watertown, MA 02472 (“Licensor”), and SWEDISH ORPHAN BIOVITRUM AB (publ), a Swedish public company having its principal place of business at SE-112 76 Stockholm, Sweden (“Licensee”). Capitalized terms used and not otherwise defined herein shall have the meanings given such terms in the Agreement to the extent defined therein.
This Agreement is based on the model Patent License Non-exclusive Agreement adopted by the U.S. Public Health Service ("PHS") Technology Transfer Policy Board for use by components of the National Institutes of Health ("NIH"), the Centers for Disease...Agreement • March 7th, 2024 • Cartesian Therapeutics, Inc. • Pharmaceutical preparations
This Patent License Agreement, hereinafter referred to as the "Agreement", consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D ((Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options).
ContractNon-Exclusive Patent License Agreement • March 7th, 2024 • Cartesian Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential.
